ClinicalTrials.gg
CompletedNCT00928486Updated Nov 20, 2019Results posted

A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma

A Phase 3 interventional study of Lenalidomide and Dexamethasone in Multiple Myeloma, sponsored by Celgene. Completed at 8 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-11-20.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.

Enrollment
180th of 249
25 · median 50
Started
2009
with 14 others
Phase 3
44 of 249
3 open now
Registered
60th of 249
by date
Lead sponsor
14 of 249
Celgene

Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 180th largest by enrollment, is one of 15 that started in 2009, is one of 44 in phase 3, and was the 60th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies testing lenalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of lenalidomide with dexamethasone in Japanese patients with previously treated multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must understand and voluntarily sign the form
  • Age ≥ 20 years at the time of signing the informed consent form
  • Subjects with previously treated multiple myeloma defined as follows:

    • Subjects must have received at least 1 prior anti-myeloma drug treatment regimen; and
    • Considered to have progression of disease (PD) that occurred either during or following the completion of the last anti-myeloma treatment regimen utilized prior to enrollment into this study
  • Measurable levels of M-protein in serum (greater than or equal to 0.5 g/dL [5g/L]) or urine (greater than or equal to 0.2 g excreted in a 24-hour collection sample)
  • (ECOG) performance status of 0 - 2
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • Females of (FCBP) must agree to use one or more of the following forms of or abstain from heterosexual contact completely and have the male partners use a condom on the occasion of heterosexual contact in the following periods below:

    • For at least 28 days before starting study drug (in particular, the subject must abstain from heterosexual contact for 2 weeks prior to prescribing lenalidomide).
    • During the treatment phase (including the dose withholding period) For at least 28 days after the discontinuation/completion of the study drug (Methods of contraception)
    • Birth control pills
    • Intrauterine device (IUD)
    • Bilateral tubal ligation (FCBP must be referred to a health care provider who is familiar with contraceptive methods, if needed).
  • Male subject must agree to use a condom during sexual contact with female irrespective of pregnancy potential
  • Subjects must agree that study drug must be immediately discontinued, if pregnancy or a positive pregnancy test does occur in a female study subject or the partner of a male study subject during study participation

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females
  • Subjects with a history of acute myocardial infarction within the past 6 months before starting the study drugs
  • Subjects with any history or concurrent conditions of deep vein thrombosis or pulmonary embolus within the past 3 years before starting study drugs
  • Subjects with tuberculous diseases, herpes simplex keratitis, systemic mycosis or other active infectious diseases
  • Subjects with non-controlled diabetes, hypertension, digestive ulcer or glaucoma
  • Subjects with posterior subcapsular cataracts
  • Subjects with peripheral neuropathy of ≥Grade 2
  • Subjects with any history or concurrent conditions which the Principal Investigator / subinvestigators consider inappropriate for participation in this study, and subjects with a serious disease or a mental disease, which is considered to become more risky if the subjects participate in this study.
  • Subjects with a history of desquamative (blistering) rash while taking thalidomide
  • Subjects with a history of using lenalidomide
  • Subjects who have used thalidomide within 28 days before starting the study drugs
  • Subjects with a history of to dexamethasone
  • Subjects who discontinued treatment due to grade 3 or 4 toxicity from high dose dexamethasone
  • Subjects with a surgical wound after a visceral surgery performed recently
  • Subjects who have undergone radiation therapy within 14 days before starting the study drugs
  • Subjects who have used a chemotherapeutic agent, an immunomodulating agent or a study drug (a drug not commercially available) intended for the treatment of multiple myeloma (MM) within 28 days before starting the study drug
  • Subjects with any history or concurrent conditions of , other than MM, unless the subject has been free of the disease for 3 years:

    • Basal cell carcinoma of the skin,
    • Squamous cell carcinoma of the skin,
    • Carcinoma in situ of the cervix,
    • Carcinoma in situ of the breast,
    • Incidental histologic finding of prostate cancer Tumor, Lymph Nodes, (TNM) stage of T1a or T1b)
  • Known (HIV) infection or HIV-1 positivity
  • Subjects who have been diagnosed as an virus (HBV) carrier
  • Subjects who are applicable to any of the following abnormal laboratory findings:

    • : \< 1,000 /μL (1.0×10\^9 /L)
    • count: \<75,000 /μL (75×10\^9 /L)
    • (AST)/serum glutamic oxaloacetic transaminase (SGOT) or alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT): > 3.0 times the upper limit of the standard range
    • : \< 30 mL/min
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Lenalidomide and Dexamethasone

    Lenalidomide 25mg by mouth (PO) once daily (QD) on Days 1-21 of each 28 day cycle; When creatinine (CrCl) clearance \<60 mL/min, the initial dose was 10mg and the dose could be increased to 15mg after 2 cycles if the investigator judged therapeutic effect was insufficient and tolerability was acceptable. Dexamethasone 40 mg by PO once QD on days 1-4, 9-12 and 17-20 of each 28 day cycle for the first 4 cycles and Days 1-4 for the remaining cycles beginning at Cycle 5.

    Drug: Lenalidomide · Drug: Dexamethasone

Interventions

  • Lenalidomide 25mg PO for (days 1 - 21) of a 28-day cycle

    Also known as: CC-5013, Revlimid

  • Dexamethasone 40 mg by mouth (PO) daily (QD) on days 1-4, 9-12 and 17-20 of each 28 day cycle

    Also known as: Decadron

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAE)

    A TEAE was defined as any AE that started on or after the first dose of study drug, and within End of Study (EOS) (28 days after the last dose of study drug received). A serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability; is a congenital anomaly/birth defect; or constitutes an important medical event. The intensity of AEs were graded 1 to 5 according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. For all other AEs not described in the CTCAE criteria, the intensity was assessed by the investigator as mild grade (Grade 1), moderate (grade 2), severe (grade 3), life-threatening (grade 4) or death (grade 5)

    Time frame: Day 1 of study drug through 28 days after the last dose of study drug; maximum treatment duration was 60.3 weeks

Secondary outcomes

  1. Myeloma Response Rate

    Overall myeloma response rate was determined by the investigator using the Myeloma Response Determination Criteria adapted from Bladé criteria. A responder is any patient who showed at least a partial response. Overall myeloma response rate is defined as the percentage of participants who achieved a Complete Response (CR), plus a Remission Response (RR), plus a Partial Response (PR). A CR is the disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks. RR is a 75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. PR is a 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion.

    Time frame: From the time of the first dose of study drug to study completion; median duration on study was 42.1 weeks

  2. Kaplan-Meier Estimates of Duration of Response (DoR)

    Duration of response was defined as the time from the first observation of a response (CR, RR or PR) to the first documented disease progression or relapse. For participants who did not progress during the study, duration of response was censored at the last adequate response assessment showing evidence of no disease progression. Disease progression is defined as an increase in M-protein serum monoclonal paraprotein and/or urine paraprotein or evidence of bone marrow plasmacytosis and plasma cells, an appearance of new or existing soft tissue plasmacytomas, an appearance of new or existing lytic bone lesions and/or hypercalcemia \>11.5mg/dL

    Time frame: From the time of the first dose of study drug to study completion; the median duration on study was 42.1 weeks

07

Results

Posted Jun 14, 2016

Participant flow

Participant flow — Overall Study
MilestoneLenalidomide and Dexamethasone
Started25
Efficacy evaluable (ee)24
Completed15
Not completed10
Withdrew: Adverse event2
Withdrew: Disease progression7
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Participants Experiencing Treatment-Emergent Adverse Events (TEAE)

A TEAE was defined as any AE that started on or after the first dose of study drug, and within End of Study (EOS) (28 days after the last dose of study drug received). A serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability; is a congenital anomaly/birth defect; or constitutes an important medical event. The intensity of AEs were graded 1 to 5 according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. For all other AEs not described in the CTCAE criteria, the intensity was assessed by the investigator as mild grade (Grade 1), moderate (grade 2), severe (grade 3), life-threatening (grade 4) or death (grade 5)

Time frame:
Day 1 of study drug through 28 days after the last dose of study drug; maximum treatment duration was 60.3 weeks
Reported as:
Number · participants
Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAE)
participantsLenalidomide and Dexamethasone
Any Adverse Event (AE)25
Drug-Related AE25
Grade 3-4 Adverse Event22
Drug-Related Grade 3-4 AE21
Serious Adverse Event (SAE)12
Drug-Related SAE9
AE Leading to Study Drug Discontinuation4
Related AE Leading to Len/Dex Discontinuation2
AE leading to dose reduction or interruption17
Related AE leading to dose reduction/interruption16
SecondaryMyeloma Response Rate

Overall myeloma response rate was determined by the investigator using the Myeloma Response Determination Criteria adapted from Bladé criteria. A responder is any patient who showed at least a partial response. Overall myeloma response rate is defined as the percentage of participants who achieved a Complete Response (CR), plus a Remission Response (RR), plus a Partial Response (PR). A CR is the disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks. RR is a 75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. PR is a 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion.

Time frame:
From the time of the first dose of study drug to study completion; median duration on study was 42.1 weeks
Reported as:
Number · percentage of participants
Myeloma Response Rate
percentage of participantsLenalidomide and Dexamethasone
Myeloma Response Rate62.5
SecondaryKaplan-Meier Estimates of Duration of Response (DoR)

Duration of response was defined as the time from the first observation of a response (CR, RR or PR) to the first documented disease progression or relapse. For participants who did not progress during the study, duration of response was censored at the last adequate response assessment showing evidence of no disease progression. Disease progression is defined as an increase in M-protein serum monoclonal paraprotein and/or urine paraprotein or evidence of bone marrow plasmacytosis and plasma cells, an appearance of new or existing soft tissue plasmacytomas, an appearance of new or existing lytic bone lesions and/or hypercalcemia \>11.5mg/dL

Time frame:
From the time of the first dose of study drug to study completion; the median duration on study was 42.1 weeks
Reported as:
Median · weeks
Kaplan-Meier Estimates of Duration of Response (DoR)
weeksLenalidomide and Dexamethasone
Kaplan-Meier Estimates of Duration of Response (DoR)NA (NA to NA)

Adverse events

Collected over Day 1 of study drug through 28 days after the last dose of study drug; maximum treatment duration was 60.3 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide and Dexamethasone—12/25 (48%)25/25 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventLenalidomide and Dexamethasone
DeathGeneral disorders1/25
PyrexiaGeneral disorders1/25
CholecystitisHepatobiliary disorders1/25
Hepatic function abnormalHepatobiliary disorders1/25
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/25
Waldenstrom's macroglobulinaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/25
Myocardial infarctionCardiac disorders1/25
Vertigo positionalEar and labyrinth disorders1/25
CataractEye disorders1/25
DiarrhoeaGastrointestinal disorders1/25
Most frequent other events
Showing 10 of 52
Most frequent other events
EventLenalidomide and Dexamethasone
NeutropeniaBlood and lymphatic system disorders20/25
LymphopeniaBlood and lymphatic system disorders16/25
LeukopeniaBlood and lymphatic system disorders15/25
ThrombocytopeniaBlood and lymphatic system disorders13/25
ConstipationGastrointestinal disorders13/25
NasopharyngitisInfections and infestations12/25
RashSkin and subcutaneous tissue disorders8/25
AnaemiaBlood and lymphatic system disorders7/25
MalaiseGeneral disorders7/25
Fibrin D dimer increasedInvestigations6/25

Baseline characteristics

Safety Population = includes all participants who received at least one dose of study drug

Age, Continuous
Age, Continuous(years)Lenalidomide and Dexamethasone
Mean62.1 ± 9.99
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide and Dexamethasone
Female13
Male12
Region of Enrollment
Region of Enrollment(participants)Lenalidomide and Dexamethasone
Japan25
08

Study locations

8 sites
  • Nagoya Medical Center
    Nagoya-city, Aichi 460-0001, Japan
  • Nagoya City University Hospital
    Nagoya-city, Aichi 467-8602, Japan
  • Fukuoka University Hospital
    Fukuoka-city, Fukuoka 814-0180, Japan
  • Kyoto Prefectural University of Medicine
    Kyoto-city, Kyoto 602-8566, Japan
  • Niigata Cancer Center Hospital
    Niigata-city, Niigata 951-5866, Japan
  • Osaka Red Cross Hospital
    Osaka-city, Osaka 543-8555, Japan
  • Tokushima University
    Tokushima-city, Tokushima 770-8503, Japan
  • Keio University Hospital
    Tokyo, 160-8582, Japan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2009 to primary completion in Sep 2010, 16 months.

Results were first posted in Jun 2016, 5 years 9 months after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 16 months is below that.

Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2009
First posted
Jun 26, 2009
StartActual
Apr 28, 2009
Primary completionActual
Sep 10, 2010
CompletionActual
Sep 10, 2010
Results first posted
Jun 14, 2016
Last update
Nov 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00928486
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jun 26, 2009
Start date
Apr 28, 2009
Primary completion
Sep 10, 2010
Completion
Sep 10, 2010
Results posted
Jun 14, 2016
Last update
Nov 20, 2019

Study contacts

Masaaki Takatoku, MD
study director · Celgene KK

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenalidomide · Dexamethasone

Start the discussion